Medicare AdvantageJuly 1, 2021
Medical drug benefit clinical criteria update
On March 25, 2021, and April 8, 2021, the Pharmacy and Therapeutics (P&T) Committee approved the following clinical criteria applicable to the medical drug benefit for Anthem and AMH Health, LLC. These policies were developed, revised, or reviewed to support clinical coding edits.
Visit Clinical Criteria to search for specific policies. If you have questions or would like additional information, use this email.
Please see the explanation/definition for each category of clinical criteria below:
- New: newly published criteria
- Revised: addition or removal of medical necessity requirements, new document number
- Updates marked with an asterisk (*) notate that the criteria may be perceived as more restrictive
Please share this notice with other members of your practice and office staff.
Note: The clinical criteria listed below applies only to the medical drug benefits contained within the member’s medical policy. This does not apply to pharmacy services.
Effective date |
Document number |
Clinical Criteria title |
New or revised |
July 16, 2021 |
ING-CC-0195* |
Abecma (idecabtagene vicleucel) |
New |
July 16, 2021 |
ING-CC-0191* |
Pepaxto (melphalan flufenamide; melflufen) |
New |
July 16, 2021 |
ING-CC-0192* |
Cosela (trilaciclib) |
New |
July 16, 2021 |
ING-CC-0193* |
Evkeeza (evinacumab) |
New |
July 16, 2021 |
ING-CC-0194* |
Cabenuva (cabotegravir extended-release; rilpivirine extended-release) Injection |
New |
July 16, 2021 |
ING-CC-0125 |
Opdivo (nivolumab) |
Revised |
July 16, 2021 |
ING-CC-0064 |
Interleukin-1 Inhibitors |
Revised |
July 16, 2021 |
ING-CC-0159* |
Scenesse (afamelanotide) |
Revised |
July 16, 2021 |
ING-CC-0151 |
Yescarta (axicabtagene ciloleucel) |
Revised |
July 16, 2021 |
ING-CC-0145* |
Libtayo (cemiplimab-rwlc) |
Revised |
July 16, 2021 |
ING-CC-0130* |
Imfinzi (durvalumab) |
Revised |
July 16, 2021 |
ING-CC-0127 |
Darzalex (daratumumab) and Darzalex Faspro (daratumumab and hyaluronidase-fihj) |
Revised |
July 16, 2021 |
ING-CC-0075* |
Rituximab Agents for Non-Oncologic Indications |
Revised |
PUBLICATIONS: July 2021 Connecticut Provider News
To view this article online:
Or scan this QR code with your phone